Authors

Latest:

Key Takeaways and Future Questions in Perioperative GC/GEJC

Panelists discuss the key takeaways, including the establishment of durvalumab plus FLOT as the new standard requiring proper laparoscopic staging and multidisciplinary care. Future questions focus on optimizing treatment for nonresponders and developing more personalized therapeutic approaches.

Paz Polak, PhD

Latest:

Dr. Polak on Evaluation of Cancer Genomes in Ghana Utilizing Liquid Biopsies

Paz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.

Giselle Sholler, MD

Latest:

Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.

Parul N Barry, MD

Latest:

Dr Barry on the Rationale for Using Partial Breast Irradiation in Breast Cancer Management

Parul N Barry, MD, discusses the integration of partial breast irradiation therapy into the treatment of patients with breast cancer.

Emre Yekeduz, MD

Latest:

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Helen Ajufo, MD

Latest:

Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS Analysis

Expert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.

James H. Doroshow, MD

Latest:

Dr. Doroshow on Increasing Patient Accrual to Clinical Trials During the COVID-19 Pandemic

James H. Doroshow, MD, discusses strategies that were implemented to increase patient accrual to clinical trials during the COVID-19 pandemic.

OncLive Article with Dr. Erika Hamilton

Allison Cushman-Vokoun, MD, PhD, FCAP

Allison Cushman-Vokoun, MD, PhD, FCAP, is the Henry F. Krous Professor of Pathology, a professor in the UNMC Department of Pathology, Microbiology and Immunology, director of the Division of Diagnostic Molecular Pathology and Human Genetics, medical director of the Molecular Diagnostics and Personalized Medicine Laboratory at Nebraska Medicine, director of the Molecular Genetic Pathology Fellowship Program, and associate director of the UMNC MD-PhD Scholars Program

Latest:

FDA Approval Insights: Oncomine DX Express Test Companion Diagnostic for Sunvozertinib in Non–Small Cell Lung Cancer: With Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP

Drs Ganti and Cushman discuss the launch of the Oncomine DX Express Test, as well as the benefits and limitations of rapid next-generation sequencing.

Francesco Maura, MD

Latest:

Dr. Maura on the Challenges of Whole-Genome Sequencing in Multiple Myeloma

Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.

Laahn Ho Foster, MD

Latest:

Dr Foster on Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma After Transplant

Laahn Foster, MD, shares data on daratumumab and lenalidomide vs lenalidomide alone as maintenance in newly diagnosed multiple myeloma after transplant.

Jeremy Force, DO

Latest:

Dr. Force on the Efficacy of Trastuzumab Deruxtecan in the DESTINY-Breast02 Trial for HER2+ Breast Cancer

Jeremy Force, DO, discusses the efficacy of trastuzumab deruxtecan in pretreated patients with HER2-positive breast cancer on the phase 3 DESTINY-Breast02 trial.

Jun Zhang, MD, PhD, University of Kansas Medical Center

Latest:

Updates in Systemic Therapy for Non-Metastatic Lung Cancer

Sara A. Hurvitz, MD, FACP

Sara A. Hurvitz, MD, FACP, is a medical oncologist, senior vice president, professor in, and director of the Clinical Research Division at Fred Hutchinson Cancer Center in Seattle, Washington. She also serves as the Smith Family Endowed Chair in Women’s Health.

Latest:

Exciting New Data for TNBC Therapies

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.

Christopher L. Moertel, MD

Christopher Moertel, MD is the Kenneth and Betty Jayne Dahlberg Professor of Pediatrics in the University of Minnesota School of Medicine. He is the medical director of the Katie Hageboeck Children's Cancer Research Fund Clinic and leads the Pediatric Brain Tumor Program at the Comprehensive Neurofibromatosis Clinic.

Latest:

MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD

Dr Moertel discusses the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib and selumetinib.

Tarita Thomas, MD, PhD, MBA

Latest:

Thomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual Meeting

Drs Thomas and Lukas discusses highlights in brain cancer research from the 2024 ASCO Annual Meeting.

Elena Maroto-Martin, PhD

Latest:

Dr Maroto-Martin on the Mechanism of MZB1-Targeted CAR T-Cell Therapy in Myeloma and Waldenström Macroglobulinemia

Elena Maroto-Martin, PhD, discusses the mechanism of action and therapeutic rationale for an MZB1-targeted CAR T-cell therapy in of multiple myeloma and Waldenström macroglobulinemia.

Christina Poh, MD

Latest:

Dr Poh on the Preliminary Efficacy of Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma

Christina Poh, MD, discusses results from the phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Francesca Palandri, MD

Latest:

Dr Palandri on Efforts to Elucidate the Role of Predictive Markers for Ruxolitinib in Myelofibrosis

Francesca Palandri, MD, discusses research needed to clarify the role of predictive markers for ruxolitinib response in myelofibrosis.

Burak Zeybek, MD

Latest:

Dr Zeybek on the Investigation of Neoadjuvant Olaparib in Newly Diagnosed BRCA-Mutant Ovarian Cancer

Burak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.